Regulus Therapeutics is a clinical-stage biopharmaceutical company focused on microRNA-targeting drugs. They have a product candidate, RGLS8429, in Phase 1b trial for autosomal dominant polycystic kidney disease. The company also develops preclinical products for target organ-selective delivery strategies.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.8 |